Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther. 2009;11:244.
Pincus T, Bergman MJ, Maclean R, Yazici Y. Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology “vital signs” for usual clinical care. Rheum Dis Clin N Am. 2009;35:779–86.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.
Wells G, Becker JC, Teng J, Dougados M, Schiff M, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954–60.
Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272–7.
FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis. 2012;71:358–62.
Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–91.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH. Committee on Prognosis Studies in SLE Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40.
American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria - The American College of Rheumatology: response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418–3426.
Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S37–46.
Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford). 1999;38:878–82.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–40.
Lequesne M. Indices of severity and disease activity for osteoarthritis. Semin Arthritis Rheum. 1991;20(6 Suppl 2):48–54.
Vallejo MA, Rivera J, Esteve-Vives J, Rejas J, Group ICAF. A confirmatory study of the Combined Index of Severity of Fibromyalgia (ICAF*): factorial structure, reliability and sensitivity to change. Health Qual Life Outcomes. 2011;9:39.
Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16:R132.
Tatlock S, Rüdell K, Panter C, Arbuckle R, Harrold LR, et al. What outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions. Patient. 2017;10:65–79.
Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2012;63:238–45.
Huang CF, Liu JC, Huang HC, Chuang SY, Chen CI, Lin KC. Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study. Rheumatol Int. 2017;37:313–22.
Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, et al. OMERACT 7 Special Interest Group. Outcome measures for acute and chronic gout. J Rheumatol. 2005;32:2452–5.
Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol. 2009;36:2342–5.
Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.
Huang X, Du H, Gu J, Zhao D, Jiang L, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17:679–86.
Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6-month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56:2170–8.
Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69:203–12.
Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76:811–20.
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711–20.
Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125:1126–34.
Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, et al. Outcome evaluations in gout. J Rheumatol. 2007;34:1381–5.
Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, et al. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011;38:1467–70.
Sarkin A, Gnanasakthy A, Lale R, Choi K, Hirsch J. A composite endpoint measure to consolidate multidimensional impact of treatment on gouty arthritis. Open J Rheumatol Autoimmune Dis. 2013;3:159–64.
Scirè CA, Carrara G, Viroli C, Cimmino MA, Taylor WJ, et al. Study Group for the Kick-Off of the Italian Network for Gout Study. Development and first validation of a disease activity score for gout. Arthritis Care Res (Hoboken). 2016;68:1530–7.
Chinchilla SP, Doherty M, Abhishek A. Gout Activity Score has predictive validity and is sensitive to change: results from the Nottingham Gout Treatment Trial (Phase II). Rheumatology (Oxford). 2019. https://doi.org/10.1093/rheumatology/key446 [Epub ahead of print].
de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, et al. Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken). 2016;68:667–72.
Schlesinger N, Edwards NE, Khanna P, Yeo A, Lipsky PE. Evaluation of proposed criteria for evidence based development of criteria for complete response in patients with chronic refractory gout. ACR Open Rheumatology. 2019. https://doi.org/10.1002/acr2.1025.
Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72:1469–74.
Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, FM MQ, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011;38:1452–7.
Shields GE, Beard SM. A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics. 2015;33:1029–47.
Mandell BF, Yeo A, Lipsky PE. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Res Ther. 2018;20(1):286.
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.
van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000;59(Suppl 1):i28–31.
Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289(19):2554–9.
Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920.